SCHEMBL2705226

SCHEMBL2705226

COc1ccc(C(=O)c2cc(Cl)ccc2N)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
MAPT P10636 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
RECQL P46063 1/20 0.52
ABCG2 Q9UNQ0 1/20 0.52
POLB P06746 1/20 0.51
TSHR P16473 2/20 0.49
CYP3A4 P08684 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 1/20 0.49
RAB9A P51151 1/20 0.49
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
HPGD P15428 1/20 0.48
RAD52 P43351 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705487 0.89 POLB (0.66) MAPTSMN1; SMN2RECQLPOLBTSHR
SCHEMBL11576934 0.86 NPC1 (0.59) NPC1MAPTSMN1; SMN2ABCG2POLB
SCHEMBL6951763 0.84 RECQL (0.50) NPC1MAPTSMN1; SMN2RECQLPOLB
SCHEMBL8501693 0.84 PARP15 (0.51) NPC1MAPTSMN1; SMN2RECQLRAB9A
SCHEMBL2705425 0.84 RECQL (0.65) NPC1MAPTSMN1; SMN2RECQLTSHR
SCHEMBL29244924 0.83 RECQL (0.52) NPC1MAPTSMN1; SMN2RECQLPOLB
SCHEMBL31575666 0.82 NPC1 (0.79) NPC1MAPTSMN1; SMN2ABCG2TSHR
SCHEMBL285924 0.82 NPC1 (0.79) NPC1MAPTSMN1; SMN2ABCG2TSHR
SCHEMBL3525434 0.81 MAPT (0.68) NPC1MAPTSMN1; SMN2RECQLPOLB
SCHEMBL30045087 0.81 MAPT (0.68) NPC1MAPTSMN1; SMN2RECQLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083906-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARM INC (US) 2024-03-14 US disclosed
US-20220041605-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2022-02-10 US disclosed
US-11014928-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2021-05-25 US disclosed
US-20200247810-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2020-08-06 US disclosed
US-10414770-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2019-09-17 US disclosed
US-20180134716-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2018-05-17 US disclosed
US-9765078-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-09-19 US disclosed
EP-2719698-B1 Methods for preparing aurora kinase inhibitors MILLENNIUM PHARM INC (US) 2016-10-05 EP disclosed
EP-2746285-B1 Process for the preparation of aurora kinase inhibitors MILLENNIUM PHARM INC (US) 2016-09-14 EP disclosed
US-20160185782-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2016-06-30 US disclosed
US-20090299060-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-12-03 US disclosed
US-7572784-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-11 US disclosed
EP-1771450-B9 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARM INC (US) 2008-12-24 EP disclosed
EP-1905773-A2 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-04-02 EP disclosed
EP-1771450-B1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARM INC (US) 2007-12-19 EP disclosed
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed
CN-101014603-A Compounds and methods for inhibiting mitosis by inhibiting aurora kinase MILLENNIUM PHARM INC (US) 2007-08-08 CN disclosed
EP-1771450-A2 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-04-11 EP disclosed
WO-2005111039-A2 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-24 WO disclosed
US-20050256102-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247810-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-20050256102-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-10414770-B2 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-20180134716-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-11014928-B2 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-20090299060-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-20220041605-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-20160185782-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885
US-20240083906-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB NPC1 688/4885MAPT 676/4885SMN1; SMN2 3426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.